Comment on "drug screening for ALS using patient-specific induced pluripotent stem cells"

Science Translational Medicine

Volumn 5, Issue 188, 2013, Pages

  Bilican, Bilada ^a,b   Serio, Andrea ^a,b   Barmada, Sami J ^c,d   Nishimura, Agnes Lumi ^e   Sullivan, Gareth J ^b   Carrasco, Monica ^f   Phatnani, Hemali P ^f   Puddifoot, Clare A ^a   Story, David ^a,b   Fletcher, Judy ^b   Park, In Hyun ^g   Friedman, Brad A ^h   Daley, George Q ⁱ   Wyllie, David J A ^a   Hardingham, Giles E ^a   Wilmut, Ian ^b   Finkbeiner, Steven ^c,d   Maniatis, Tom ^f   Shaw, Christopher E ^e   Chandran, Siddharthan ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h HARVARD UNIVERSITY   (United States)

ⁱ HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHIONINE; TAR DNA BINDING PROTEIN; VALINE;

AMYOTROPHIC LATERAL SCLEROSIS; BIOTECHNOLOGY; CELL COUNT; CELL POPULATION; CELL SURVIVAL; DRUG SCREENING; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETIC TRANSFECTION; HUMAN; HUNTINGTON CHOREA; MOTONEURON; MUTATIONAL ANALYSIS; NERVE CELL NECROSIS; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME;

AMYOTROPHIC LATERAL SCLEROSIS; DRUG EVALUATION, PRECLINICAL; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MOTOR NEURONS;

EID: 84880556157     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3005065     Document Type: Review

References (5)

1. N. Egawa, S. Kitaoka, K. Tsukita, M. Naitoh, K. Takahashi, T. Yamamoto, F. Adachi, T. Kondo, K. Okita, I. Asaka, T. Aoi, A. Watanabe, Y. Yamada, A. Morizane, J. Takahashi, T. Ayaki, H. Ito, K. Yoshikawa, S. Yamawaki, S. Suzuki, D. Watanabe, H. Hioki, T. Kaneko, K. Makioka, K. Okamoto, H. Takuma, A. Tamaoka, K. Hasegawa, T. Nonaka, M. Hasegawa, A. Kawata, M. Yoshida, T. Nakahata, R. Takahashi,M. C. N.Marchetto, F. H. Gage, S. Yamanaka, H. Inoue, Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci. Transl. Med. 4, 145ra104 (2012).
2. B. Bilican, A. Serio, S. J. Barmada, A. L. Nishimura, G. J. Sullivan, M. Carrasco, H. P. Phatnani, C. A. Puddifoot, D. Story, J. Fletcher, I.-H. Park, B.A. Friedman, G.Q.Daley, D. J. A. Wyllie, G. E. Hardingham, I. Wilmut, S. Finkbeiner, T. Maniatis, C. E. Shaw, S. Chandran, Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc. Natl. Acad. Sci. U.S.A. 109, 5803-5808 (2012).
3. M. Arrasate, S. Finkbeiner, Automated microscope system for determining factors that predict neuronal fate. Proc. Natl. Acad. Sci. U.S.A. 102, 3840-3845 (2005).
4. M. Arrasate, S. Mitra, E. S. Schweitzer, M. R. Segal, S. Finkbeiner, Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810 (2004).
5. HD iPSC Consortium, Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 11, 264-278 (2012).